{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T19:00:57Z","timestamp":1767466857643,"version":"3.48.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,3]]},"DOI":"10.7759\/cureus.100704","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T18:55:58Z","timestamp":1767466558000},"source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-Like Peptide-1 Receptor Agonists as a Non-surgical Alternative to Bariatric Surgery for Weight Loss: A Review"],"prefix":"10.7759","author":[{"given":"Chuh","family":"Steven","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thangwaritorn","family":"Skylynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haghighat","family":"Bardya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhalla","family":"Megha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vuong","family":"Helen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fateh","family":"Entabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhakar","family":"Pemminati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.7.740","article-title":"Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States","volume":"28","author":"Kim N","year":"2022","unstructured":"Kim N, Wang J, Burudpakdee C, et al.. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. J Manag Care Spec Pharm. 2022, 28:740-52. 10.18553\/jmcp.2022.28.7.740","journal-title":"J Manag Care Spec Pharm"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/biom11101426","article-title":"Obesity-an update on the basic pathophysiology and review of recent therapeutic advances","volume":"11","author":"Gjermeni E","year":"2021","unstructured":"Gjermeni E, Kirstein AS, Kolbig F, et al.. Obesity-an update on the basic pathophysiology and review of recent therapeutic advances. Biomolecules. 2021, 11:1426. 10.3390\/biom11101426","journal-title":"Biomolecules"},{"key":"ref3","unstructured":"Potential Candidates for Weight-Loss Surgery. (2020). Accessed. October 29, 2025: https:\/\/www.niddk.nih.gov\/health-information\/weight-management\/bariatric-surgery\/potential-candidates."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1503\/cjs.002011","article-title":"Managing complications associated with laparoscopic Roux-en-Y gastric bypass for morbid obesity","volume":"55","author":"Griffith PS","year":"2012","unstructured":"Griffith PS, Birch DW, Sharma AM, Karmali S. Managing complications associated with laparoscopic Roux-en-Y gastric bypass for morbid obesity. Can J Surg. 2012, 55:329-36. 10.1503\/cjs.002011","journal-title":"Can J Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-024-07056-0","article-title":"One anastomosis gastric bypass as revisional surgery following sleeve gastrectomy: a systematic review and meta-analysis","volume":"34","author":"Nakanishi H","year":"2024","unstructured":"Nakanishi H, Mosleh KA, Al-Kordi M, et al.. One anastomosis gastric bypass as revisional surgery following sleeve gastrectomy: a systematic review and meta-analysis. Obes Surg. 2024, 34:429-41. 10.1007\/s11695-024-07056-0","journal-title":"Obes Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-025-03215-x","article-title":"One anastomosis gastric bypass (OAGB): a scoping review","volume":"25","author":"Ort\u00edz-G\u00f3mez JE","year":"2025","unstructured":"Ort\u00edz-G\u00f3mez JE, Gonz\u00e1lez-Barajas AI, Guevara-D\u00edaz JA, Mancilla-Galindo J, Kammar-Garc\u00eda A, Guerrero-Gutierrez MA. One anastomosis gastric bypass (OAGB): a scoping review. BMC Surg. 2025, 25:471. 10.1186\/s12893-025-03215-x","journal-title":"BMC Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-018-3525-0","article-title":"Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding","volume":"29","author":"O'Brien PE","year":"2019","unstructured":"O'Brien PE, Hindle A, Brennan L, et al.. Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obes Surg. 2019, 29:3-14. 10.1007\/s11695-018-3525-0","journal-title":"Obes Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility","volume":"166","author":"Jalleh RJ","year":"2024","unstructured":"Jalleh RJ, Marathe CS, Rayner CK, et al.. Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility. Endocrinology. 2024, 166:bqae155. 10.1210\/endocr\/bqae155","journal-title":"Endocrinology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.462","article-title":"Glucagon-like peptide agonists: a prospective review","volume":"7","author":"Mariam Z","year":"2024","unstructured":"Mariam Z, Niazi SK. Glucagon-like peptide agonists: a prospective review. Endocrinol Diabetes Metab. 2024, 7:e462. 10.1002\/edm2.462","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1398059","article-title":"Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity","volume":"11","author":"Tamayo-Trujillo R","year":"2024","unstructured":"Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, et al.. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Front Nutr. 2024, 11:1398059. 10.3389\/fnut.2024.1398059","journal-title":"Front Nutr"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren JR","year":"2021","unstructured":"Lundgren JR, Janus C, Jensen SB, et al.. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021, 384:1719-30. 10.1056\/NEJMoa2028198","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2025.04.018","article-title":"Semaglutide effects on energy balance are mediated by Adcyap1(+) neurons in the dorsal vagal complex","volume":"37","author":"Teixidor-Deulofeu J","year":"2025","unstructured":"Teixidor-Deulofeu J, Blid Sk\u00f6ldheden S, Font-Giron\u00e8s F, Feje\u0161 A, Ruud J, Engstr\u00f6m Ruud L. Semaglutide effects on energy balance are mediated by Adcyap1(+) neurons in the dorsal vagal complex. Cell Metab. 2025, 37:1530-1546.e6. 10.1016\/j.cmet.2025.04.018","journal-title":"Cell Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard J","year":"2021","unstructured":"Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Adv Ther. 2021, 38:2821-39. 10.1007\/s12325-021-01710-0","journal-title":"Adv Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.78575","article-title":"A system-based review on effects of glucagon-like peptide-1 receptor agonists: benefits vs risks","volume":"17","author":"Fadel LP","year":"2025","unstructured":"Fadel LP, Thao G, Chitre T, et al.. A system-based review on effects of glucagon-like peptide-1 receptor agonists: benefits vs risks. Cureus. 2025, 17:e78575. 10.7759\/cureus.78575","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5","volume":"28","author":"Kushner RF","year":"2020","unstructured":"Kushner RF, Calanna S, Davies M, et al.. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020, 28:1050-61. 10.1002\/oby.22794","journal-title":"Obesity (Silver Spring)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22594","article-title":"A protocol to deliver intensive behavioral therapy (IBT) for obesity in primary care settings: the MODEL-IBT program","volume":"27","author":"Wadden TA","year":"2019","unstructured":"Wadden TA, Tsai AG, Tronieri JS. A protocol to deliver intensive behavioral therapy (IBT) for obesity in primary care settings: the MODEL-IBT program. Obesity (Silver Spring). 2019, 27:1562-6. 10.1002\/oby.22594","journal-title":"Obesity (Silver Spring)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2021.12.008","article-title":"Semaglutide for the treatment of obesity","volume":"33","author":"Chao AM","year":"2023","unstructured":"Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023, 33:159-66. 10.1016\/j.tcm.2021.12.008","journal-title":"Trends Cardiovasc Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2022.11.001","article-title":"Obesity pharmacotherapy: incretin action in the central nervous system","volume":"44","author":"Boer GA","year":"2023","unstructured":"Boer GA, Hay DL, Tups A. Obesity pharmacotherapy: incretin action in the central nervous system. Trends Pharmacol Sci. 2023, 44:50-63. 10.1016\/j.tips.2022.11.001","journal-title":"Trends Pharmacol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong CK","year":"2024","unstructured":"Wong CK, McLean BA, Baggio LL, et al.. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab. 2024, 36:130-143.e5. 10.1016\/j.cmet.2023.11.009","journal-title":"Cell Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175048","article-title":"Suppression of angiotensin II-activated NOX4\/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension","volume":"927","author":"Banks TE","year":"2022","unstructured":"Banks TE, Rajapaksha M, Zhang LH, Bai F, Wang NP, Zhao ZQ. Suppression of angiotensin II-activated NOX4\/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension. Eur J Pharmacol. 2022, 927:175048. 10.1016\/j.ejphar.2022.175048","journal-title":"Eur J Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut JM","year":"2023","unstructured":"Yabut JM, Drucker DJ. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev. 2023, 44:14-32. 10.1210\/endrev\/bnac018","journal-title":"Endocr Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1953","article-title":"Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes","volume":"45","author":"Pradhan R","year":"2022","unstructured":"Pradhan R, Yin H, Yu O, Azoulay L. Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes. Diabetes Care. 2022, 45:819-29. 10.2337\/dc21-1953","journal-title":"Diabetes Care"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide","volume":"12","author":"Smits MM","year":"2021","unstructured":"Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021, 12:645563. 10.3389\/fendo.2021.645563","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway JT","year":"2024","unstructured":"Hathaway JT, Shah MP, Hathaway DB, et al.. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024, 142:732-9. 10.1001\/jamaophthalmol.2024.2296","journal-title":"JAMA Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-019-00335-3","article-title":"Metformin: mechanisms in human obesity and weight loss","volume":"8","author":"Yerevanian A","year":"2019","unstructured":"Yerevanian A, Soukas AA.  Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep. 2019, 8:156-64. 10.1007\/s13679-019-00335-3","journal-title":"Curr Obes Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1605","article-title":"Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study","volume":"170","author":"Apolzan JW","year":"2019","unstructured":"Apolzan JW, Venditti EM, Edelstein SL, et al.. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019, 170:682-90. 10.7326\/M18-1605","journal-title":"Ann Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 Randomized Clinical Trial","volume":"325","author":"Wadden TA","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, et al.. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021, 325:1403-13. 10.1001\/jama.2021.1831","journal-title":"JAMA"},{"key":"ref32","article-title":"Lorcaserin (Belviq): a selective serotonin 5-HT2C agonist in the treatment of obesity","volume":"38","author":"Gustafson A","year":"2013","unstructured":"Gustafson A, King C, Rey JA. Lorcaserin (Belviq): a selective serotonin 5-HT2C agonist in the treatment of obesity. P T. 2013, 38:525-34.","journal-title":"P T"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2017.06.004","article-title":"Lorcaserin plus lifestyle modification for weight loss maintenance: rationale and design for a randomized controlled trial","volume":"59","author":"Tronieri JS","year":"2017","unstructured":"Tronieri JS, Alfaris N, Chao AM, et al.. Lorcaserin plus lifestyle modification for weight loss maintenance: rationale and design for a randomized controlled trial. Contemp Clin Trials. 2017, 59:105-12. 10.1016\/j.cct.2017.06.004","journal-title":"Contemp Clin Trials"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2003873","article-title":"Cancer risk associated with lorcaserin - the FDA's review of the CAMELLIA-TIMI 61 trial","volume":"383","author":"Sharretts J","year":"2020","unstructured":"Sharretts J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L. Cancer risk associated with lorcaserin - the FDA's review of the CAMELLIA-TIMI 61 trial. N Engl J Med. 2020, 383:1000-2. 10.1056\/NEJMp2003873","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801868","article-title":"Decreased plasma orexin-a levels in obese individuals","volume":"26","author":"Adam JA","year":"2002","unstructured":"Adam JA, Menheere PP, van Dielen FM, Soeters PB, Buurman WA, Greve JW. Decreased plasma orexin-a levels in obese individuals. Int J Obes Relat Metab Disord. 2002, 26:274-6. 10.1038\/sj.ijo.0801868","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084803","article-title":"Acute post-bariatric surgery increase in orexin levels associates with preferential lipid profile improvement","volume":"9","author":"Gupta A","year":"2014","unstructured":"Gupta A, Miegueu P, Lapointe M, et al.. Acute post-bariatric surgery increase in orexin levels associates with preferential lipid profile improvement. PLoS One. 2014, 9:e84803. 10.1371\/journal.pone.0084803","journal-title":"PLoS One"},{"key":"ref37","article-title":"Topiramate and phentermine","author":"Johnson DB","year":"2025","unstructured":"Johnson DB, Quick J. Topiramate and phentermine. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0930","article-title":"Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release","volume":"37","author":"Garvey WT","year":"2014","unstructured":"Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, Troupin B. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014, 37:3309-16. 10.2337\/dc14-0930","journal-title":"Diabetes Care"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21649","article-title":"Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings","volume":"24","author":"Moldovan CP","year":"2016","unstructured":"Moldovan CP, Weldon AJ, Daher NS, et al.. Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings. Obesity (Silver Spring). 2016, 24:2344-50. 10.1002\/oby.21649","journal-title":"Obesity (Silver Spring)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22430","article-title":"Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort","volume":"27","author":"Lewis KH","year":"2019","unstructured":"Lewis KH, Fischer H, Ard J, et al.. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity (Silver Spring). 2019, 27:591-602. 10.1002\/oby.22430","journal-title":"Obesity (Silver Spring)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2014.04.004","article-title":"Naltrexone\/bupropion for obesity: an investigational combination pharmacotherapy for weight loss","volume":"84","author":"Billes SK","year":"2014","unstructured":"Billes SK, Sinnayah P, Cowley MA. Naltrexone\/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014, 84:1-11. 10.1016\/j.phrs.2014.04.004","journal-title":"Pharmacol Res"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S84778","article-title":"Naltrexone HCI\/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives","volume":"10","author":"Tek C","year":"2016","unstructured":"Tek C. Naltrexone HCI\/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives. Patient Prefer Adherence. 2016, 10:751-9. 10.2147\/PPA.S84778","journal-title":"Patient Prefer Adherence"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.46747\/cfp.6909627","article-title":"Naltrexone-bupropion for weight loss","volume":"69","author":"Thomas B","year":"2023","unstructured":"Thomas B, Lindblad AJ, Luu T, Paige A. Naltrexone-bupropion for weight loss. Can Fam Physician. 2023, 69:627. 10.46747\/cfp.6909627","journal-title":"Can Fam Physician"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01319-7","article-title":"The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials","volume":"16","author":"Liu Y","year":"2024","unstructured":"Liu Y, Han F, Xia Z, Sun P, Rohani P, Amirthalingam P, Sohouli MH. The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials. Diabetol Metab Syndr. 2024, 16:93. 10.1186\/s13098-024-01319-7","journal-title":"Diabetol Metab Syndr"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.4.270.34882","article-title":"Orlistat, a new lipase inhibitor for the management of obesity","volume":"20","author":"Heck AM","year":"2000","unstructured":"Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 2000, 20:270-9. 10.1592\/phco.20.4.270.34882","journal-title":"Pharmacotherapy"},{"key":"ref46","article-title":"Recent advances in dietary and drug treatment of obesity","volume":"19","author":"Essa SA","year":"2025","unstructured":"Essa SA, Alganga HS, Ebrahim NA. Recent advances in dietary and drug treatment of obesity. Libyan Journal of Medical Research. 2025, 19:105-12.","journal-title":"Libyan Journal of Medical Research"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-025-08338-x","article-title":"Comparative analysis of the effectiveness and frequency of complications of different techniques of laparoscopic sleeve gastrectomy in patients with obesity","author":"Ruziyev U","year":"2025","unstructured":"Ruziyev U, Teshayev O, Niyazova N, Babadjanov A, Parmar C. Comparative analysis of the effectiveness and frequency of complications of different techniques of laparoscopic sleeve gastrectomy in patients with obesity. Obes Surg. 2025, 10.1007\/s11695-025-08338-x","journal-title":"Obes Surg"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-022-02501-z","article-title":"Single anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S): experience from a high-bariatric volume center","volume":"407","author":"Pennestr\u00ec F","year":"2022","unstructured":"Pennestr\u00ec F, Sessa L, Prioli F, et al.. Single anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S): experience from a high-bariatric volume center. Langenbecks Arch Surg. 2022, 407:1851-62. 10.1007\/s00423-022-02501-z","journal-title":"Langenbecks Arch Surg"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.14775","article-title":"Sleeve gastrectomy","volume":"324","author":"Brajcich BC","year":"2020","unstructured":"Brajcich BC, Hungness ES. Sleeve gastrectomy. JAMA. 2020, 324:908. 10.1001\/jama.2020.14775","journal-title":"JAMA"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2018.04.011","article-title":"Sleeve gastrectomy: metabolic surgical procedure of choice?","volume":"29","author":"Aminian A","year":"2018","unstructured":"Aminian A. Sleeve gastrectomy: metabolic surgical procedure of choice?. Trends Endocrinol Metab. 2018, 29:531-4. 10.1016\/j.tem.2018.04.011","journal-title":"Trends Endocrinol Metab"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2015.05.021","article-title":"Laparoscopic adjustable gastric banding: efficacy and consequences over a 13-year period","volume":"212","author":"Toolabi K","year":"2016","unstructured":"Toolabi K, Golzarand M, Farid R. Laparoscopic adjustable gastric banding: efficacy and consequences over a 13-year period. Am J Surg. 2016, 212:62-8. 10.1016\/j.amjsurg.2015.05.021","journal-title":"Am J Surg"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2022.10.020","article-title":"Long-term outcome after biliopancreatic diversion with duodenal switch: a single-center experience with up to 20 years follow-up","volume":"19","author":"S\u00fcsstrunk J","year":"2023","unstructured":"S\u00fcsstrunk J, Schneider R, Peterli R, Slawik M, Woelnerhanssen B, Kraljevi\u0107 M. Long-term outcome after biliopancreatic diversion with duodenal switch: a single-center experience with up to 20 years follow-up. Surg Obes Relat Dis. 2023, 19:83-90. 10.1016\/j.soard.2022.10.020","journal-title":"Surg Obes Relat Dis"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-023-06716-x","article-title":"Surgical management of intra-gastric balloon complications, single-center experience, and literature review","volume":"33","author":"Foula MS","year":"2023","unstructured":"Foula MS, Amer NM, Zakaria H, et al.. Surgical management of intra-gastric balloon complications, single-center experience, and literature review. Obes Surg. 2023, 33:2718-24. 10.1007\/s11695-023-06716-x","journal-title":"Obes Surg"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.87a.19097","article-title":"Liposuction: concepts, safety, and techniques in body-contouring surgery","volume":"87","author":"Wu S","year":"2020","unstructured":"Wu S, Coombs DM, Gurunian R. Liposuction: concepts, safety, and techniques in body-contouring surgery. Cleve Clin J Med. 2020, 87:476. 10.3949\/ccjm.87a.19097","journal-title":"Cleve Clin J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjae074","article-title":"Risks and complications rate in liposuction: a systematic review and meta-analysis","volume":"44","author":"Comerci AJ","year":"2024","unstructured":"Comerci AJ, Arellano JA, Alessandri-Bonetti M, et al.. Risks and complications rate in liposuction: a systematic review and meta-analysis. Aesthet Surg J. 2024, 44:NP454-63. 10.1093\/asj\/sjae074","journal-title":"Aesthet Surg J"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-025-08150-7","article-title":"Outcomes and safety of one anastomosis gastric bypass (OAGB): a three-year retrospective study","volume":"35","author":"Mebarek H","year":"2025","unstructured":"Mebarek H, Toumi HF, Nimeri A. Outcomes and safety of one anastomosis gastric bypass (OAGB): a three-year retrospective study. Obes Surg. 2025, 35:3918-25. 10.1007\/s11695-025-08150-7","journal-title":"Obes Surg"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.2229","article-title":"Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss, comorbidities, and reflux at 10 years in adult patients with obesity: the Sleevepass randomized clinical trial","volume":"157","author":"Salminen P","year":"2022","unstructured":"Salminen P, Gr\u00f6nroos S, Helmi\u00f6 M, et al.. Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss, comorbidities, and reflux at 10 years in adult patients with obesity: the Sleevepass randomized clinical trial. JAMA Surg. 2022, 157:656-66. 10.1001\/jamasurg.2022.2229","journal-title":"JAMA Surg"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and risks of bariatric surgery in adults: a review","volume":"324","author":"Arterburn DE","year":"2020","unstructured":"Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020, 324:879-87. 10.1001\/jama.2020.12567","journal-title":"JAMA"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020502","article-title":"Obesity: a global health challenge demanding urgent action","volume":"13","author":"Abad-Jim\u00e9nez Z","year":"2025","unstructured":"Abad-Jim\u00e9nez Z, Vezza T. Obesity: a global health challenge demanding urgent action. Biomedicines. 2025, 13:502. 10.3390\/biomedicines13020502","journal-title":"Biomedicines"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/417366-glucagon-like-peptide-1-receptor-agonists-as-a-non-surgical-alternative-to-bariatric-surgery-for-weight-loss-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T18:55:59Z","timestamp":1767466559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/417366-glucagon-like-peptide-1-receptor-agonists-as-a-non-surgical-alternative-to-bariatric-surgery-for-weight-loss-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":59,"URL":"https:\/\/doi.org\/10.7759\/cureus.100704","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,3]]}}}